Exciting deal with Scopely on improved terms 5 top tier titles have now been signed during 2021… …an...
Redeye raises its forecast and Base case following Sdiptech’s Capital Markets Day, with the increase...
Redeye comments on Enviro’s ISCC certification of its tyre pyrolysis oil and recovered carbon black,...
Redeye sees no big drama in the news announced last week.
We give a brief comment on the news that the first patients have been included in Vicore’s pivotal C...
Redeye welcomes the continued commercial orders for NeoDynamics in Germany and Switzerland.
The initiation of Asarina Pharma’s phase IIa study in Tourette’s has been postponed until December 2...
Redeye comments on the latest agreement in Norway.
Redeye has increased estimates and fair value for Aspire as the company continues to perform stronge...
Redeye updates their view and estimates for Evolution Gaming Group due to strong performance from th...
BankNordik is set to distribute DKK 450m (DKK ~47 per share) in Q4 following the sale of its Danish ...
Bonesupports börsvärde halverades när bolaget presenterade resultatet från den svårtolkade Fortify-s...
Redeye comments on yesterday’s directed share issue of EUR 4 million.
Redeye sees vast potential in Inzile’s bold strategic move.
Tellusgruppens intäkter fortsätter att öka. Bolaget ökade sina intäkter med cirka 17 procent under d...
The exercise period for the warrants of series TO 1 that were issued in connection with Curasight's ...
FDA regards Calliditas amended application as a major amendment very late in the approval process an...
Annexin Pharmaceuticals announced yesterday positive results from its anticipated phase I study, a m...
When Biovica announced that the FDA was not yet ready to accept Biovica’s updated application, this ...
Redeye initiates coverage on Penneo, A Danish auditor-focused digital signing solution growing rapid...
